Comparative Orthopaedic Research Laboratory, Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Montreal, St-Hyacinthe, Quebec, Canada.
Equine Vet J. 2023 May;55(3):534-550. doi: 10.1111/evj.13600. Epub 2022 Jun 19.
Focal bone microcracks with osteoclast recruitment and bone lysis, may reduce fracture resistance in racehorses. As current imaging does not detect all horses at risk for fracture, the discovery of novel serum biomarkers of bone resorption or osteoclast activity could potentially address this unmet clinical need. The biology of equine osteoclasts on their natural substrate, equine bone, has never been studied in vitro and may permit identification of specific biomarkers of their activity.
(1) Establish osteoclast cultures on equine bone, (2) Measure biomarkers (tartrate resistant acid phosphatase isoform 5b [TRACP-5b] and C-terminal telopeptide of type I collagen [CTX-I]) in vitro and (3) Study the effects of inflammation.
In vitro experiments.
Haematopoietic stem cells, from five equine sternal bone marrow aspirates, were differentiated into osteoclasts and cultured either alone or on equine bone slices, with or without a pro-inflammatory stimulus (IL-1β or LPS). CTX-I and TRACP-5b were immunoassayed in the media. Osteoclast numbers and bone resorption area were assessed.
TRACP-5b increased over time in osteoclast cultures without bone (p < 0.0001) and correlated with osteoclast number (r = 0.63, p < 0.001). CTX-I and TRACP-5b increased with time for cultures with bone (p = 0.002; p = 0.02 respectively), correlated with each other (r = 0.64, p < 0.002) and correlated with bone resorption (r = 0.85, p < 0.001; r = 0.82, p < 0.001 respectively). Inflammation had no measurable effects.
Specimen numbers limited.
Equine osteoclasts were successfully cultured on equine bone slices and their bone resorption quantified. TRACP-5b was shown to be a biomarker of equine osteoclast number and bone resorption for the first time; CTX-I was also confirmed to be a biomarker of equine bone resorption in vitro. This robust equine specific in vitro assay will help the study of osteoclast biology.
具有破骨细胞募集和骨溶解的局灶性骨微裂纹可能会降低赛马的骨折抵抗力。由于目前的影像学检查无法检测出所有有骨折风险的马匹,因此发现新的骨吸收或破骨细胞活性的血清生物标志物可能会满足这一未满足的临床需求。在体外研究马的破骨细胞在其天然基质——马骨上的生物学特性从未进行过,这可能允许鉴定其活性的特定生物标志物。
(1)在马骨上建立破骨细胞培养物,(2)在体外测量生物标志物(抗酒石酸酸性磷酸酶同工酶 5b[TRACP-5b]和 I 型胶原 C 末端肽[CTX-I]),(3)研究炎症的影响。
体外实验。
从五匹马的胸骨骨髓抽吸物中分离出造血干细胞,分化为破骨细胞,并在单独或与马骨切片一起培养,有或没有促炎刺激物(IL-1β 或 LPS)。CTX-I 和 TRACP-5b 在培养基中进行免疫测定。评估破骨细胞数量和骨吸收面积。
在没有骨的破骨细胞培养物中,TRACP-5b 随时间推移而增加(p<0.0001),并与破骨细胞数量相关(r=0.63,p<0.001)。CTX-I 和 TRACP-5b 在有骨的培养物中随时间增加(p=0.002;p=0.02),彼此相关(r=0.64,p<0.002),并与骨吸收相关(r=0.85,p<0.001;r=0.82,p<0.001)。炎症没有可测量的影响。
样本数量有限。
成功地在马骨切片上培养了马的破骨细胞,并对其骨吸收进行了量化。TRACP-5b 首次被证明是马破骨细胞数量和骨吸收的生物标志物;CTX-I 也被证实是体外马骨吸收的生物标志物。这种强大的马特异性体外检测方法将有助于破骨细胞生物学的研究。